News & Updates

The combination of corticosteroid (CS) therapy with remdesivir (RDV) has noninferior survival outcomes relative to CS monotherapy in patients hospitalized with the coronavirus disease 2019 (COVID-19), reports a recent study.

The early addition of ivermectin to standard of care (SoC)* in high-risk patients with mild-to-moderate COVID-19 did not prevent progression to severe disease compared with SoC alone, according to results of the I-TECH** trial conducted in Malaysia.

There is an increased rate of hepatitis C virus (HCV) reinfection among people who inject drugs after the scale-up of direct-acting antivirals, reports a recent Scotland study.

Patients with pneumonia appear to be at increased risk of developing chronic otitis media, a study has found.

Use of famotidine in the treatment of outpatients with mild-to-moderate COVID-19 is safe and well tolerated, leading to rapid resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity, according to the results of a phase II trial.

Patients with non-severe coronavirus disease 2019 (COVID-19) who have worse glycaemic status are more likely to deteriorate clinically, but glycaemic status does not adversely impact neutralizing antibody (NAb) responses, researchers from the University of Hong Kong have shown.

The risk of COVID-19 is substantially reduced in adults who receive a third “booster” dose of the BNT162b2 vaccine regardless of their age, according to a study from Israel.

Research from the University of Hong Kong (HKU) demonstrates that intranasal influenza-based booster vaccination following PD1-based receptor-binding domain (RBD) DNA vaccine induces mucosal and systemic immunity for effective prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both upper and lower respiratory systems of mice.

A study by the University of Hong Kong (HKU) has found that immune sera from mRNA-based BNT162b2 and inactivated CZ02 vaccine recipients have substantially reduced neutralizing antibody titres against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).